Perspective Therapeutics, Inc.

NYSE American CATX

Perspective Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -80.42 M

Perspective Therapeutics, Inc. Net Cash Used For Investing Activities is USD -80.42 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -430.41% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Perspective Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 24.34 M, a 168.76% change year over year.
Perspective Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -35.40 M, a -9,984.33% change year over year.
Perspective Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -351.00 K, a -16.23% change year over year.
Perspective Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -302.00 K, a -104.58% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NYSE American: CATX

Perspective Therapeutics, Inc.

CEO	Mr. Johan M. Spoor
IPO Date	Nov. 10, 2005
Location	United States
Headquarters	350 Hills Street
Employees	116
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Key trends

Past 5 years